Materialise(MTLS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, consolidated revenue grew by 6.8% year-on-year, reaching EUR 70.2 million, with a gross profit margin of 58.1% [13][14] - Adjusted EBIT for Q4 was EUR 4 million, representing a margin of 5.7%, while net profit was EUR 6.2 million, more than double the previous year's figure [13][25] - The net cash position improved to EUR 70.8 million, an increase of over EUR 3 million compared to the prior quarter [14][25] Business Line Data and Key Metrics Changes - Materialise Medical segment revenue grew by over 16% in Q4, reaching EUR 37 million, driven by a 23% increase in medical devices and services revenue [15][20] - Software segment revenue remained stable at around EUR 11 million, with recurring revenue growing by 4% year-on-year [21] - Manufacturing segment revenue declined by 2% year-on-year to EUR 22.2 million, with a negative adjusted EBITDA of -EUR 2.2 million [22][23] Market Data and Key Metrics Changes - Materialise Medical accounted for 53% of consolidated revenue in Q4, while manufacturing contributed 31% and software 16% [15] - The company faced unfavorable foreign exchange effects, primarily from a weaker US dollar, impacting the top line [15] Company Strategy and Development Direction - The company aims to continue investing in the Materialise Medical and Software segments while maintaining disciplined cost control, particularly in Manufacturing [29] - A dual listing on Euronext Brussels was established to access a broader investor audience and enhance operational flexibility [5] Management Comments on Operating Environment and Future Outlook - Management expects the Materialise Medical segment to continue growing at a double-digit pace, while the Manufacturing segment may face ongoing macroeconomic headwinds [29] - The company anticipates revenue for 2026 to be in the range of EUR 273 million to EUR 283 million [29] Other Important Information - A share buyback program of up to EUR 30 million was announced, with acquisitions of 187,500 shares for just below $1 million to date [5] - The company has made significant R&D investments to support future growth in the Medical segment [20] Q&A Session Summary Question: Will manufacturing be down year-over-year? - Management confirmed that manufacturing is expected to be flat to down due to a weaker industrial climate, particularly in Europe [35][36] Question: What percentage of manufacturing is for prototyping applications? - The company has not disclosed this percentage but acknowledged that prototyping remains a significant part of the business [37] Question: Can costs be reduced to achieve EBITDA breakeven in manufacturing? - Management indicated a focus on segments with growth potential and unique capabilities, while also working on cost optimization in the manufacturing segment [38] Question: Was there a one-time cost in Q4 OpEx? - Management clarified that Q4 OpEx included non-recurring costs related to the Euronext listing, which should be excluded from baseline projections [39]